Caris Life Sciences Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值低估,在医疗设备与耗材行业排名65/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价38.11。中期看,股价处于平稳状态。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Caris Life Sciences Inc评分
相关信息
行业排名
65 / 208
全市场排名
162 / 4582
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
38.111
目标均价
+34.38%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Caris Life Sciences Inc亮点
亮点风险
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代码CAI
公司Caris Life Sciences Inc
CEOHalbert (David Dean)
网址https://www.carislifesciences.com/
常见问题
Caris Life Sciences Inc(CAI)的当前股价是多少?
Caris Life Sciences Inc(CAI)的当前股价是 27.940。
Caris Life Sciences Inc的股票代码是什么?
Caris Life Sciences Inc的股票代码是CAI。
Caris Life Sciences Inc股票的52周最高点是多少?
Caris Life Sciences Inc股票的52周最高点是42.500。
Caris Life Sciences Inc股票的52周最低点是多少?
Caris Life Sciences Inc股票的52周最低点是22.860。
Caris Life Sciences Inc的市值是多少?
Caris Life Sciences Inc的市值是7.88B。
Caris Life Sciences Inc的净利润是多少?
Caris Life Sciences Inc的净利润为-378.26M。
现在Caris Life Sciences Inc(CAI)的股票是买入、持有还是卖出?
根据分析师评级,Caris Life Sciences Inc(CAI)的总体评级为买入,目标价格为38.111。
Caris Life Sciences Inc(CAI)股票的每股收益(EPS TTM)是多少
Caris Life Sciences Inc(CAI)股票的每股收益(EPS TTM)是-5.049。